| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | -0.0061 | 0.9 |
| mRNA | BRD-K97651142 | CTRPv2 | pan-cancer | AAC | 0.0062 | 0.9 |
| mRNA | JQ-1:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0056 | 0.9 |
| mRNA | BRD-K19103580 | CTRPv2 | pan-cancer | AAC | -0.006 | 0.9 |
| mRNA | salermide | CTRPv2 | pan-cancer | AAC | -0.0073 | 0.9 |
| mRNA | CCT036477 | CTRPv2 | pan-cancer | AAC | 0.0053 | 0.9 |
| mRNA | TG-101348 | CTRPv2 | pan-cancer | AAC | 0.0051 | 0.9 |
| mRNA | lenvatinib | CTRPv2 | pan-cancer | AAC | -0.0056 | 0.9 |
| mRNA | triazolothiadiazine | CTRPv2 | pan-cancer | AAC | 0.004 | 0.9 |
| mRNA | Crizotinib | gCSI | pan-cancer | AAC | -0.0076 | 0.9 |